This version substantially revises and extends Version 1.0. The primary hypothesis has been reformulated within a protein corona framework: PS80 is now presented as an efficiency amplifier of a baseline apolipoprotein adsorption mechanism (H0) rather than a prerequisite, broadening the scope of the hypothesis to all aluminum-adjuvanted vaccines. The title has been updated accordingly. New material includes: A dedicated introduction to protein corona dynamics and kinetic competition in Section 2. A two-level hypothesis structure (H1 primary + H0 corollary) in Section 5, with an additional falsifiable prediction (H0a). A new subsection 7.2 on organ-specific distribution via LDLR expression and its relationship to autoimmune disease patterns, including ASIA syndrome (Shoenfeld (2) Gherardi et al. demonstratedthat vaccine aluminum particles exhibit long-term biopersistence and can translocate to the brain via intracellularphagocyte-mediated transport; (3) Mold, Umar, King and Exley (2018) reported extraordinary aluminumconcentrations in post-mortem brain tissue from donors with autism spectrum disorder, with aluminum foundpredominantly in microglia-like and non-neuronal inflammatory cells. Implications: If confirmed, this mechanism would represent an additional pathway for aluminum adjuvantneurodeposition. The protein corona framework further explains interindividual variability in neurological adverseevent profiles. A structurally analogous parallel hypothesis is articulated regarding PEGylated lipid nanoparticles inmRNA vaccines. Both hypotheses are falsifiable and amenable to direct experimental testing
Añaños et al. (Sat,) studied this question.